Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

Who May Qualify: - Nulliparous women aged 18 years or more - Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor - Singleton pregnancy - Evolutive pregnancy between 9 and 14 weeks of gestation - Women affiliated to a French Social Security Insurance or equivalent social protection - Written willing to sign a consent form Who Should NOT Join This Trial: - Major fetal abnormality - Regular treatment with aspirin (including antiphospholipid syndrome) - Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia) - Women protected by law. - Women included in another interventional study. Always talk to your doctor about whether this trial is right for you.